

Company name:	SanBio Co., Ltd.	
Representative:	Keita Mori, Representative Director and President (TSE Mothers Code: 4592)	
Contact:	Yoshihiro Kakutani, Corporate Officer of Management Administration (TEL: +81-3-6264-3481)	
Company name:	CareNet, Inc.	
Representative:	Katsuhiro Fujii, President and COO (TSE Mothers Code: 2150)	
Contact:	Toshiro Ichimasa, Operating Officer, Manager, Corporate Planning and Management Division (TEL: +81-3-5214-5800)	
Company name:	Medical Incubator Japan K.K.	
Representative:	Jun Katsura, President & Co-CEO	
Contact:	Mitsuhiro Hata, Director, Chief Administrative Officer (TEL: +81-3-4590-0240)	
Company name:	Vital KSK Holdings, Inc.	
Representative:	Taisuke Murai, President & CEO (TSE 1 Code: 3151)	
Contact:	Masaaki Tsugoshi, Director, Head of Business Planning (TEL: +81-22-218-6132)	
Company name:	Astem Inc.	
Representative:	Tsuguo Yoshimura, President	
Contact:	Forest Holdings Inc. Ryuji Eguchi, Director, Executive Officer, Head of Corporate Planning Division (TEL: +81-92-477-5804)	


Notice regarding an equity and business alliance between five companies for joint research on the appropriate use, adoption, and stable distribution of regenerative cell medicine SB623

SanBio Co., Ltd. (representative: Keita Mori, headquarters: Chuo-ku, Tokyo; hereinafter SanBio) hereby

announces that it has resolved to enter into an equity and business alliance (hereinafter the Agreement) with CareNet, Inc. (representative: Katsuhiro Fujii, headquarters: Chiyoda-ku, Tokyo; hereinafter CareNet), Medical Incubator Japan K.K., (representative: Jun Katsura, headquarters: Minato-ku, Tokyo; hereinafter Medical Incubator), Vital KSK Holdings, Inc. (representative: Taisuke Murai, headquarters: Setagaya-ku, Tokyo; hereinafter Vital KSK Holdings), and Astem Inc. (representative: Tsuguo Yoshimura, headquarters: Oita, Oita Prefecture; hereinafter Astem) for joint research on the appropriate use, adoption, and stable distribution of regenerative cell medicine SB623.

1. Overview of the business alliance

Since the beginning of the 21st century, R&D of regenerative cell medicines has been actively promoted around the world, and as a result, has now reached the stage of products being approved and launched. Regenerative cell medicines are expected to spread widely in the coming years. However, medical institutions and peripheral companies in the healthcare industry including pharmaceutical distributors are largely inexperienced in the handling of regenerative cell medicines. They are currently under pressure to accelerate preparations for promoting and marketing regenerative medicine products in ways best suited to their features. Under such circumstances, the five companies above have been examining best ways to pioneer the appropriate use, adoption, and stale distribution of regenerative cell medicines in Japan. Because regenerative cell medicines are a cutting-edge field, the five companies agreed that appropriate use, adoption, and stable distribution of these medicines would be best achieved by teaming up with pioneers in each specialty, and hence agreed to conduct joint research. With its regenerative cell medicine SB623 as the research target, SanBio will engage in joint research with CareNet and Medical Incubator, which have many years' experience in providing pharmaceutical information and educational programs for physicians and pharmacists, and with Vital KSK Holdings and Astem, which have knowledge and experience in pharmaceutical distribution. SanBio, CareNet, and Medical Incubator are to play a central role in research into the appropriate use and adoption of regenerative cell medicines, while SanBio, Vital KSK Holdings, and Astem will lead studies in distribution. By drawing on the knowledge and experience of each company, SanBio believes it can enhance the content and quality of joint research.



Cutting-edge regenerative cell

2. Overview of the equity alliance

Although the main goal of forming business alliance is to improve the content of joint research, the five companies have judged that they could also increase their corporate value by taking part in the alliance. Hence, to conduct the joint research in a more cooperative way and to make the best of their alliance, they have decided to enter into an equity alliance agreement.

SanBio will acquire 1,076,400 common shares in CareNet held by its largest shareholder CareNet Innovation Investment Limited Partnership (hereinafter CareNet Innovation) in an off-market transfer (9.74% of 11,048,000 outstanding shares as of August 31, 2018). CareNet, Medical Incubator, Vital KSK Holdings, and Astem will acquire in total 1.59% of outstanding shares in SanBio (49,713,533 shares as of August 31, 2018). Medical Incubator will own shares in SanBio through CareNet Innovation, which Medical Incubator manages as a general partner.

3. Profiles of companies in the equity and business alliance

(1) Profile of SanBio

(1)	Company name	SanBio Co., Ltd.		
(2)	Address	8-1 Akashi-cho, Chuo-ku, Tokyo		
(3)	Representative	Keita Mori, Representative	e Director and President	
(4)	Main business	Development, manufactur	e, and sales of regenerative cell medicines	
(5)	Capital	3,875 million yen		
(6)	Established	February 2013		
(7)	Major shareholders and	Toru Kawanishi	26.86%	
	shareholding ratios	Keita Mori	13.18%	
	(as of January 31, 2018)	Sumitomo Dainippon Phar	rma Co., Ltd. 6.19%	
		Tenjin Limited	6.10%	
		J.P. Morgan Bank Luxemb	oourg S.A. 385576 1.42%	
		RBC IST 15 PCT Lending	Account–Client Account 1.27%	
		Japan Trustee Services Ba	ank, Ltd. (Trust Account) 1.19%	
		The Bank of New York 133	3524 1.12%	
		RBC ISB S/A DUB Nonresident/Treaty Rate		
		UCITS-Clients Account	0.87%	
		SBI Securities Co., Ltd.	0.85%	
(8)	Relationships with	Relationship with CareNet		
	partnering companies	Capital relationship	Toru Kawanishi, Executive Chairman and	
			Co-CEO of SanBio, owns 1.30% of	
			outstanding shares in CareNet (as of	
			June 30, 2018).	
			Motoyasu Ohno, Chairman and CEO of	
			CareNet, owns 0.26% of outstanding	
			shares in SanBio (as of January 31,	
			2018).	

	Personal relationship	Not applicable	
	Business relationship	Based on an outso	urcina aareement
	Business relationship	concluded in the fis	
		January 31, 2018, 3	•
		outsourced post-ma	
		SB623 to CareNet.	
	Affiliated party as	Not applicable	
	prescribed in the Rules		
	of Corporate Accounting	tinneration	
	Relationship with CareNe		
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the Rules		
	of Corporate Accounting		
	Relationship with Medical	Incubator	
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the Rules		
	of Corporate Accounting		
	Relationship with Vital KS	K Holdings	
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the Rules		
	of Corporate Accounting		
	Relationship with Astem		
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the Rules		
	of Corporate Accounting		
(9) Consolidated earnings and		st three fiscal years	
Fiscal year ended	January 2016	January 2017	January 2018
Net assets (million yen)	6,366	4,594	853
		/	
Total assets (million yen)	8,271	6,292	5,193

Operating revenue (million yen)	1,174	949	490
Operating income (million yen)	(1,125)	(1,932)	(4,378)
Ordinary income (million yen)	(1,172)	(2,166)	(3,947)
Net income attributable to owners of parent (million yen)	(988)	(1,835)	(3,940)
Net income per share (yen)	(22.67)	(40.88)	(86.85)
Dividend per share (yen)	None	None	None

(2) Profile of CareNet

(1)	Company name	CareNet, Inc.		
(2)	Head office	1-5-6 Kudan-minami, Chiyoda-ku, Tokyo		
(3)	Representative	Katsuhiro Fujii, President and COO		
(4)	Main business	Provides pharmaceutica	al sales support for pharmaceutical c	ompanies
		Provides medical conter	nt for physicians and other health ca	re
		professionals		
(5)	Capital	627 million yen		
(6)	Established	July 1996		
(7)	Major shareholders and	CareNet Innovation Inve	estment Limited Partnership	28.64%
	shareholding ratios	BNYM Non-Treaty DTT		7.42%
	(as of June 30, 2018)	Astem Inc.		6.20%
		Vital-Net, Inc.		3.72%
		Millennium Partners Co.	, Ltd.	3.65%
		KSK Co., Ltd.		2.48%
		Motoyasu Ohno		2.42%
		UBS Securities LLC-HF	S Customer Segregated Account	1.62%
		Kanji Fujii 1.54%		1.54%
		Goldman Sachs International 1.37%		1.37%
(8)	Relationships with	Relationship with SanBie	0	
	partnering companies	Capital relationship	Toru Kawanishi, Executive Chairm	an and
			Co-CEO of SanBio, owns 1.30% o	f
			outstanding shares in CareNet (as	of June
			30, 2018).	
			Motoyasu Ohno, Chairman and Cl	EO of
			CareNet, owns 0.26% of outstandi	•
			in SanBio (as of January 31, 2018)).
		Personal relationship	Not applicable	
		Business relationship	Based on an outsourcing agreeme	-
			CareNet has received orders for m	arket
			research from SanBio.	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		

Accounting	
Relationship with CareN	let Innovation
Capital relationship	CareNet Innovation owns 28.64% of
	outstanding shares in CareNet (as of June
	30, 2018).
Personal relationship	Not applicable
Business relationship	CareNet and CareNet Innovation have
	concluded an equity alliance agreement.
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Relationship with Medica	al Incubator
Capital relationship	Mitsuhiro Hata, Director of Medical
	Incubator, owns 0.75% of outstanding
	shares in CareNet (as of June 30, 2018).
	Medical Incubator owns 28.64% of
	outstanding shares in CareNet through
	CareNet Innovation, which Medical
	Incubator manages as a general partner (as
	of June 30, 2018).
Personal relationship	Motoyasu Ohno, Chairman and CEO of
	CareNet, was appointed as Chairman &
	Co-CEO of Medical Incubator.
Business relationship	CareNet and Medical Incubator have
	concluded a business alliance agreement
	and a consortium agreement.
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Relationship with Vital K	SK Holdings
Capital relationship	Vital-Net and KSK (subsidiaries of Vital KSK
	Holdings) respectively owns 3.72% and
	2.48% of outstanding shares in CareNet (as
	of June 30, 2018).
Personal relationship	Not applicable
Business relationship	Not applicable
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Accounting	

	Relationship with Astem	1	
	Capital relationship	Astem owns 6.20% of	f outstanding shares in
		CareNet (as of June 3	80, 2018).
	Personal relationship	Not applicable	
	Business relationship	CareNet and Astem h	ave concluded an
		agreement regarding	cooperation on DVD
		sales.	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
(9) Consolidated earnings and	financial position for the la	ast three fiscal years*	
Fiscal year ended	December 2015	December 2016	December 2017
Total net assets (million yen)	1,424	1,528	1,904
Total assets (million yen)	1,723	2,029	2,778
Net assets per share (yen)	131.40	140.80	176.57
Net sales (million yen)	1,911	2,196	2,854
Operating profit (million yen)	153	194	407
Ordinary income (million yen)	147	197	408
Net income attributable to			
parent company shareholders	132	158	464
(million yen)			
Net income per share (yen)	12.25	14.62	42.64
Dividend per share (yen)	10.00	8.00	6.00

*Note: CareNet carried out a two-for-one stock split effective October 1, 2017. Net assets per share and net income per share were calculated based on the assumption that the stock split was carried out at the beginning of the fiscal year ended December 31, 2015.

(3) Profile of CareNet Innovation

(1)	Company name	CareNet Innovation Investment Limited Partnership	
(2)	Head office	3-5-6 Kita-aoyama, Minato-ku, Tokyo	
(3)	Representative	General partner: Millennium Partners Co., Ltd.	
		Mitsuhiro Hata, Managing Partner	
		General partner: Medical Incubator Japan K.K.	
		Jun Katsura, President & Co-CEO	
(4)	Main business	Purchases and owns stocks, share acquisition rights, bonds with	
		share acquisition rights, convertible bonds with stock acquisition	
		rights, and other investment securities issued by companies	
(5)	Total capital	1,360,636,638 yen	
(6)	Date established	November 25, 2008	
(7)	Investors and capital	Astem Inc. 48.70%	
	contribution ratios	Vital-Net, Inc.	29.22%

	(as of June 30, 2018)	KSK Co., Ltd.	19.48%
		IC Solutions Co., Ltd.	2.58%
(8)	Relationships with	Relationship with SanB	io
	partnering companies	Capita relationship	Not applicable
		Personal relationship	Not applicable
		Business relationship	Not applicable
		Affiliated party as	Not applicable
		prescribed in the	
		Rules of Corporate	
		Accounting	
		Relationship with Carel	Net
		Capital relationship	CareNet Innovation owns 28.64% of
			outstanding shares in CareNet (as of June
			30, 2018).
		Personal relationship	Not applicable
		Business relationship	CareNet Innovation and CareNet have
			concluded an equity alliance agreement.
		Affiliated party as	Not applicable
		prescribed in the	
		Rules of Corporate	
		Accounting	
		Relationship with Media	cal Incubator
		Capital relationship	Medical Incubator owns 0.01% of interest in
			CareNet Innovation as a general partner.
		Personal relationship	Medical Incubator is serving as the
			representative of CareNet Innovation as a
			general partner.
		Business relationship	Medical Incubator executes business
			operations of CareNet Innovation as a
			general partner.
		Affiliated party as	Not applicable
		prescribed in the	
		Rules of Corporate	
		Accounting	
		Relationship with Vital k	<pre>K Holdings</pre>
		Capital relationship	Capital contributions from Vital-Net and
		,	KSK (subsidiaries of Vital KSK Holdings)
			account for 29.22% and 19.48%,
			respectively, of total capital in CareNet
			Innovation.
		Personal relationship	Not applicable
		Business relationship	Not applicable

	Affiliated party as	Not applicable
	prescribed in the	
	Rules of Corporate	
	Accounting	
	Relationship with Astem	
	Capital relationship	Astem contributed to 48.70% of total capital
		in CareNet Innovation (as of June 30, 2018).
	Personal relationship	Not applicable
	Business relationship	Not applicable
	Affiliated party as	Not applicable
	prescribed in the	
	Rules of Corporate	
	Accounting	
(9) Consolidated earnings and	financial position for the la	ast three fiscal years
	Because CareNet Innovation is an unlisted company, its earnings	
	results and financial position shall not be disclosed.	

(4) Profile of Medical Incubator

`				
(1)	Company name	Medical Incubator Japan K.K.		
(2)	Head office	3-5-6 Kita-aoyama, Mina	ato-ku, Tokyo	
(3)	Representative	Jun Katsura, President a	& Co-CEO	
(4)	Main business	Investment activities spe	ecializing in the healthcare field	
		Incubation services for o	companies involved in development and sales	
		of healthcare products a	and services	
(5)	Capital	50 million yen		
(6)	Date established	May 15, 2018		
(7)	Major shareholders and	Mitsuhiro Hata	60.00%	
	shareholding ratios	Jun Katsura	20.00%	
	(as of June 30, 2018)	Motoyasu Ohno Office,	Ltd. 20.00%	
(8)	Relationships with	Relationship with SanBi	0	
	partnering companies	Capital relationship	Not applicable	
		Personal relationship	Not applicable	
		Business relationship	Not applicable	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		
		Accounting		
		Relationship with CareN	let	
		Capital relationship	Mitsuhiro Hata, Director of Medical	
			Incubator, owns 0.75% of outstanding	
			shares in CareNet (as of June 30, 2018).	
			Medical Incubator owns 28.64% of	

	en tetera d'anna hanna in Oana Nat thursach
	outstanding shares in CareNet through
	CareNet Innovation, which Medical
	Incubator manages as a general partner (as of June 30, 2018).
Personal relationship	Motoyasu Ohno, Chairman and CEO of
	CareNet, was appointed as Chairman &
	Co-CEO of Medical Incubator.
Business relationship	Medical Incubator have concluded a
	business alliance agreement and a
	consortium agreement with CareNet.
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Relationship with CareN	let Innovation
Capital relationship	Medical Incubator owns 0.01% interest in
F	CareNet Innovation as a general partner.
Personal relationship	Medical Incubator is serving as the
· · · · · · · · · · · · · · · · · · ·	representative of CareNet Innovation as a
	general partner.
Business relationship	Medical Incubator executes business
	operations of CareNet Innovation as a
	general partner.
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Relationship with Vital K	SK Holdings
Capital relationship	Not applicable
Personal relationship	Not applicable
Business relationship	Vital KSK Holdings invests in CareNet
1*	Innovation, which Medical Incubator
	manages as a general partner.
Affiliated party as	Not applicable
prescribed in the	
Rules of Corporate	
Accounting	
Relationship with Astem	L
Capital relationship	Not applicable
Personal relationship	Not applicable
Business relationship	Astem invests in CareNet Innovation, which
	Medical Incubator manages as a general
	modiour mousator manages as a general

			partner.	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		
		Accounting		
(9)	Consolidated earnings and	financial position for the last three fiscal years		
		Because Medical Incubator is an unlisted company, its earnings		
		results and financial position shall not be disclosed.		

(5) Profile of Vital KSK Holdings

(1)	Company name	Vital KSK Holdings, Inc.		
(2)	Head office	1-1-12 Tsurumaki, Setagaya-ku, Tokyo		
(3)	Representative	Taisuke Murai, President and CEO		
(4)	Main business	Corporate planning and management of group companies that		
		operate pharmaceutical wholesale and retail businesses and other		
		related businesses		
(5)	Capital	5,000 million yen		
(6)	Date established	April 1, 2009		
(7)	Major shareholders and	Suzuhiko Co., Ltd. 8.66%		
	shareholding ratios	Mizuho Trust & Banking	Co., Ltd. Employee pension trust	3.91%
	(as of March 31,2018)	Employee Stock Owner	ship Association of KSK Co., Ltd.	2.73%
		Mitsubishi Tanabe Phar	ma Corporation	2.57%
		Ken Suzuki		2.36%
		Dainippon Sumitomo Pharma Co., Ltd. 2		
		Cueco Co., Ltd.		2.10%
		The Master Trust Bank of Japan, Ltd. (Trust Account)		
		Takeda Pharmaceutical Company Limited		2.05%
		Koichiro Suzuki		
(8)	Relationships with	Relationship with SanBio		
	partnering companies	Capital relationship	Not applicable	
		Personal relationship	Not applicable	
		Business relationship	Not applicable	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		
		Accounting		
		Relationship with CareNet		
		Capital relationship	Vital-Net and KSK (subsidiaries of	
			Holdings) respectively owns 3.72%	
			2.48% of outstanding shares in Ca	reNet (as
			of June 30, 2018).	
	Personal relationship Not applicable			

	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
	Relationship with CareN	let Innovation	
	Capital relationship		from Vital-Net and KSK
			KSK Holdings) account
		, for 29.22% and 19.48	U <i>i</i>
		total capital in CareNe	
		June 30, 2018).	
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
	Relationship with Medica	al Incubator	
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Vital KSK Holdings invests in CareNet	
		Innovation, which Me	dical Incubator
		manages as a genera	al partner.
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
	Relationship with Astem		
	Capital relationship		of outstanding shares
		in Forest Holdings (as	-
		Astem owns 0.35% o	f outstanding shares in
		Vital KSK Holdings (as of March 31, 2018).	
	Personal relationship	Yasuaki Yoshimura, Chairman of the Board	
		of Astem, was appoir	nted as the outside
		director of Vital KSK Holdings.	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
(9) Consolidated earnings and	financial position for the p	ast three fiscal years	
Fiscal year ended	March 2016	March 2017	March 2018

Net assets (million yen)	85,261	90,007	98,447
Total assets (million yen)	327,047	305,375	321,679
Net assets per share (yen)	1,504.04	1,586.61	1,735.04
Net sales (million yen)	621,040	581,079	565,589
Operating profit (million yen)	6,892	3,207	2,384
Ordinary profit (million yen)	10,584	6,987	6,276
Profit attributable to owners of parent (million yen)	6,556	4,778	4,467
Basic earnings per share (yen)	117.25	84.78	79.27
Dividend per share (yen)	24.00	20.00	20.00

(6) Profile of Astem

(1)	Company name	Astem Inc.		
(2)	Headquarters	2-3-8 Nishi-omichi, Oita, Oita Prefecture		
(3)	Representative	Tsuguo Yoshimura, President		
(4)	Main business	Medical general trading company that handles healthcare-related		
		products, systems, and services such as pharmaceutical drugs,		
		medical devices, and diagnostic reagents		
(5)	Capital	3,355 million yen		
(6)	Date established	May 27, 1948		
(7)	Major shareholder and	Forest Holdings Inc.	100.0%	
	shareholding ratio			
	(as of March 31, 2018)			
(8)	Relationships with	Relationship with SanBi	0	
	partnering companies	Capital relationship	Not applicable	
		Personal relationship	Not applicable	
		Business relationship	Not applicable	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		
		Accounting		
		Relationship with CareN	let	
		Capital relationship	Astem owns 6.20% of outstanding shares in	
			CareNet (as of June 30, 2018).	
		Personal relationship	Not applicable	
		Business relationship	Astem and CareNet have concluded an	
			agreement regarding cooperation on DVD	
			sales.	
		Affiliated party as	Not applicable	
		prescribed in the		
		Rules of Corporate		
		Accounting		

	Relationship with CareNet Innovation		
	Capital relationship Capital contribution from Astern accounts		
		48.70% of total capital in CareNet	
		Innovation (as of June 30, 2018).	
	Domonal relationship		
	Personal relationship	Not applicable	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
	Relationship with Medic	al Incubator	
	Capital relationship	Not applicable	
	Personal relationship	Not applicable	
	Business relationship	Astem invests in CareNet Innovation, which	
		Medical Incubator manages as a general	
		partner.	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
	Relationship with Vital KSK Holdings		
	Capital relationship	Vital-Net owns 0.52% of outstanding shares	
		in Forest Holdings (as of March 31, 2018).	
		Astem owns 0.35% of outstanding shares in	
		Vital KSK Holdings (as of March 31, 2018).	
	Personal relationship	Yasuaki Yoshimura, Chairman of the Board	
		of Astem, was appointed as the outside	
		director of Vital KSK Holdings.	
	Business relationship	Not applicable	
	Affiliated party as	Not applicable	
	prescribed in the		
	Rules of Corporate		
	Accounting		
(9) Consolidated earnings and	3	ast three fiscal years	
	Because Astem is an unlisted company, its earnings results and		
	financial position shall not be disclosed.		

4. Schedule

(1)	Date of resolution at each company's Board of Directors meeting	September 10, 2018
(2)	Conclusion date of the Agreement	September 10, 2018

5. Outlook

The Agreement is likely to have minimal impacts on earnings of SanBio, CareNet, and Vital KSK Holdings for the current fiscal year. However, the companies believe that pioneering the establishment of appropriate use, adoption, and stable distribution of regenerative cell medicines in Japan, which are expected to spread widely in the coming years, will improve their earnings in the medium to long term.